TY  - CHAP
M1  - Book, Section
TI  - Hepatocellular Carcinoma
A1  - Friedman, Lawrence S.
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
A2  - McQuaid, Kenneth R.
Y1  - 2022
N1  - 
T2  - Current Medical Diagnosis & Treatment 2022
AB  - Key  Clinical  Updates  in  Hepatocellular  CarcinomaThe  combination  of  atezolizumab,  an  immune  checkpoint  inhibitor,  and  bevacizumab,  an  antibody  to  the  VEGF  receptor,  has  been  shown  to  be  superior  to  sorafenib  and  is  now  standard  first-line  therapy.The  combination  of  nivolumab  and  ipilimumab  has  been  recommended  as  second-line  therapy  after  failure  of  sorafenib.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/23
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1184389560
ER  -